CTLA4 and melanoma: Nowadays, the main ICI options for melanoma patients are anti-programmed death 1 (anti-PD1), like nivolumab and pembrolizumab, and anti-CTLA4 in monotherapy (ipilimumab) or, only in a metastatic setting, in combination with nivolumab (anti-PD1 plus anti-CTLA4) [6].